Northwestern Medicine, working in partnership with Robert H. Lurie Comprehensive Cancer Center of Northwestern University, is proud to participate in the 2019 American Society of Clinical Oncology Annual Meeting at McCormick Place in Chicago, IL., May 31 – June 4.

Physician-scientists from Northwestern Medicine and Lurie Cancer Center will present and discuss significant advances in clinical research throughout the conference.

Reporters interested in interviewing Northwestern Medicine experts on-site at the conference should contact Kasmer Quinn at [email protected] or 312-926-0735.

Highlights of this year’s presentations include Poster Sessions:  

Saturday, June 1

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients
8:00 AM - 11:00 AM
Priya Kumthekar

Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?
8:00 AM - 11:00 AM
Lorenzo Gerratana, MD

Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors
8:00 AM - 11:00 AM
Andrew A. Davis, MD

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment
8:00 AM - 11:00 AM
Andrew A. Davis

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
1:15 PM - 4:15 PM
Wendy M Swetzig, PhD

Sunday, June 2 Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers?
8:00 AM - 11:00 AM
Christine B. Weldon, MBA

Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa)
8:00 AM - 11:00 AM
Qiang Zhang, MD, PhD

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC)
8:00 AM - 11:00 AM
Ami N. Shah, MD

NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM)
8:00 AM - 11:00 AM
Vinai Gondi, MD

NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer
8:00 AM - 11:00 AM
Vinai Gondi, MD

Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis
8:00 AM - 11:00 AM
Barbara Pro, MD

Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery
1:15 PM - 4:15 PM
Katrina Alber, MPH

Education Sessions

Friday, May 31 Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia 3:25 PM - 3:45 PM Jessica K. Altman, MD - Chair

Saturday, June 1 Fireside Chat: Including the Patient Experience in Oncology Clinical Trial Design and the Regulatory Process 8:00 AM - 8:15 AM Alicia K. Morgans, MD, MPH – Chair -Moderator

8:15 AM - 8:30 AM Regulatory Perspective Maha H. A. Hussain, MD, FACP, FASCO - Speaker

Safe and Effective Opioid Prescribing for Patients Receiving Cancer-Directed Therapy 1:45 PM - 2:05 PM Judith A. Paice, PhD, RN - Speaker

Discovering Therapeutic Metabolic Targets in Solid Tumors 1:15 PM - 1:35 PM Navdeep Chandel, PhD - Speaker

Sunday, June 2 Defining Oligometastatic Disease: Shifting Definitions and Potential Effects on Patient Outcomes 8:00 AM - 8:20 AM Edward M. Schaeffer, MD, PhD - Speaker

Liquid Biopsy: How to Interpret and Use Results in Clinical Practice 4:45 PM - 5:45 PM Clinical Case #1 Victoria Meucci Villaflor, MD - Speaker

Monday, June 3 Meet the Professors: Surgery, Liver-Directed Treatment, or Systematic Therapy—Where Are the Boundaries for Hepatic Metastases? Interventional Radiologist Perspective Riad Salem, MD – Speaker 8:20 AM - 8:40 AM

For additional sessions and posters, please visit ASCO’s online iPlanner and search Northwestern.

Register for reporter access to contact details